KIN-1901

Phase 1Small molecule

KKinevant Sciences GmbH

KIN-1901 is one of 51 small molecule programs targeting Ankylosing Spondylitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ankylosing SpondylitisActive, not recruiting

Ankylosing SpondylitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

114 competitors in Ankylosing Spondylitis

#DrugCompanyPhaseTrials

Bimzelx

UCB

Phase 3

5 2

Jyseleca

Gilead

Phase 3

4 3

Arcoxia

Novartis

Phase 3

3 4

Actemra

Roche

Phase 3

2 5

Stelara

Johnson & Johnson

Phase 3

1 6

Otezla

Amgen

Phase 3

1 7

Taltz

Eli Lilly

Phase 3

1 8

Xeljanz

PPrism Pharmaceuticals

Phase 3

3 9

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

2 10

Anjeso

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ankylosing Spondylitis1 trial

Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis

Completed·KKinevant Sciences GmbH·Phase 1·NCT04205851·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KIN-1901. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KIN-1901 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KIN-1901. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kinevant Sciences GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: KKinevant Sciences GmbH

KIN-1901

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ankylosing Spondylitis1 trial

References

Drug Info

Quick Facts

Related News